Functional Somatic Symptoms

Casper Roenneberg, Heribert Sattel, Rainer Schaefert, Peter Henningsen, Constanze Hausteiner-Wiehle, Casper Roenneberg, Heribert Sattel, Rainer Schaefert, Peter Henningsen, Constanze Hausteiner-Wiehle

Abstract

Background: Approximately 10% of the general population and around one third of adult patients in clinical populations suffer from functional somatic symptoms. These take many forms, are often chronic, impair everyday functioning as well as quality of life, and are cost intensive.

Methods: The guideline group (32 medical and psychological professional societies, two patients' associations) carried out a systematic survey of the literature and ana- lyzed 3795 original articles and 3345 reviews. The aim was to formulate empirically based recommendations that were practical and user friendly.

Results: Because of the variation in course and symptom severity, three stages of treatment are distinguished. In early contacts, the focus is on basic investigations, reassurance, and advice. For persistent burdensome symptoms, an extended, simultaneous and equitable diagnostic work-up of physical and psychosocial factors is recommended, together with a focus on information and self-help. In the pres- ence of severe and disabling symptoms, multimodal treatment includes further elements such as (body) psychotherapeutic and social medicine measures. Whatever the medical specialty, level of care, or clinical picture, an empathetic professional attitude, reflective communication, information, a cautious, restrained approach to diagnosis, good interdisciplinary cooperation, and above all active interventions for self-efficacy are usually more effective than passive, organ- focused treatments.

Conclusion: The cornerstones of diagnosis and treatment are biopsychosocial ex- planatory models, communication, self-efficacy, and interdisciplinary mangagement. This enables safe and efficient patient care from the initial presentation onwards, even in cases where the symptoms cannot yet be traced back to specific causes.

Figures

Figure 1
Figure 1
Schematic model of the etiology of bodily distress (from [4] by kind permission of Peter Henningsen)
Figure 2
Figure 2
Stepped, collaborative care according to severity: initial basic care, extended basic care, multimodal treatment/psychotherapy/rehabilitation
eFigure 1
eFigure 1
Chart describing the updated systematic literature survey: RCT, randomized controlled trial
eFigure 2
eFigure 2
*1 Evidence level classes as defined by the Oxford Centre of Evidence-based Medicine *2 As laid out in the German Program for National Care Guidelines (Programm für Nationale Versorgungsleitlinien) Upgrading/downgrading of recommendation grade (from [3])

References

    1. Hausteiner-Wiehe C, Henningsen P, Häuser W, et al. Klett-Cotta (vormals Schattauer) Vol. 1. Stuttgart: 2013. Umgang mit Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden S3-Leitlinie mit Quellentexten, Praxismaterialien und Patientenleitlinie.
    1. Schaefert R, Hausteiner-Wiehle C, Hauser W, Ronel J, Herrmann M, Henningsen P. Non-specific, functional, and somatoform bodily complaints. Dtsch Arztebl Int. 2012;109:803–813.
    1. S3-Leitlinie „Funktionelle Körperbeschwerden“. (last accessed on 4 March 2019)
    1. Henningsen P, Zipfel S, Sattel H, Creed F. Management of functional somatic syndromes and bodily distress. Psychother Psychosom. 2018;87:12–31.
    1. Hausteiner-Wiehle C, Henningsen P. Kein Befund und trotzdem krank? Stuttgart: Klett-Cotta (vormals Schattauer) 2015
    1. Henningsen P, Martin A. Somatoforme Störungen, somatische Belastungsstörung Psychotherapie. Funktions- und störungsorientiertes Vorgehen. In: Herpertz S, Caspar F, Lieb K, editors. Elsevier. München: 2016.
    1. van Gils A, Schoevers RA, Bonvanie IJ, Gelauff JM, Roest AM, Rosmalen JG. Self-help for medically unexplained symptoms: a systematic review and meta-analysis. Psychosom Med. 2016;78:728–739.
    1. van Dessel N, den Boeft M, van der Wouden JC, et al. Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database Syst Rev. 2014;11 CD011142.
    1. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2016;2 CD003200.
    1. Winkelmann A, Häuser W, Friedel E, et al. Physiotherapy and physical therapies for fibromyalgia syndrome Systematic review, meta-analysis and guideline. Schmerz. 2012;26:276–286.
    1. Arnold B, Häuser W, Arnold M, et al. Multimodale Therapie des Fibromyalgiesyndroms. Systematische Übersicht, Metaanalyse und Leitlinie. Schmerz. 2012;26:287–290.
    1. Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26:297–307.
    1. Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015;6 CD011735.
    1. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2015;10 CD008244.
    1. Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9 CD011790.
    1. Li YH, Wang FY, Feng CQ, Yang XF, Sun YH. Massage therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9 e89304.
    1. Yuan QL, Wang P, Liu L, et al. Acupuncture for musculoskeletal pain: a meta-analysis and meta-regression of sham-controlled randomized clinical trials. Sci Rep. 2016;6 30675.
    1. Bernardy K, Klose P, Busch AJ, Choy EH, Häuser W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013;9 CD009796.
    1. Lauche R, Cramer H, Dobos G, Langhorst J, Schmidt S. A systematic review and meta-analysis of mindfulness-based stress reduction for the fibromyalgia syndrome. J Psychosom Res. 2013,;75:500–510.
    1. Chao GQ, Zhang S. Effectiveness of acupuncture to treat irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2014;20:1871–1877.
    1. Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012
    1. Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5 CD005111.
    1. Aucoin M, Lalonde-Parsi MJ, Cooley K. Mindfulness-based therapies in the treatment of functional gastrointestinal disorders: a meta-analysis. Evid Based Complement Alternat Med. 2014;2014 140724.
    1. Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:937–947.
    1. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1350–1365.
    1. Schaefert R, Klose P, Moser G, Häuser W. Efficacy, tolerability, and safety of hypnosis in adult irritable bowel syndrome: systematic review and meta-analysis. Psychosom Med. 2014;76:389–398.
    1. Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1149–1172e2.
    1. Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for irritable bowel syndrome: a meta-analysis of randomized placebo-controlled trials. Medicine (Baltimore) 2016;95 e2534.
    1. Deutsche Schmerzgesellschaft. Definition, Pathophysiologie, Diagnostik und Therapie des Fibromyalgiesyndroms. (last accessed on 22 February 2019)
    1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Nationale VersorgungsLeitlinie Nicht-spezifischer Kreuzschmerz - Kurzfassung, 2nd edition. Version 1 2017 (last accessed on 22 February 2019)
    1. Martin A, Härter M, Henningsen P, Hiller W, Kröner-Herwig B, Rief W. Evidenzbasierte Leitlinie zur Psychotherapie somatoformer Störungen und assoziierter Syndrome (Vol 4) Göttingen: Hogrefe Verlag. 2013
    1. Hilderink PH, Collard R, Rosmalen JG, Oude Voshaar RC. Prevalence of somatoform disorders and medically unexplained symptoms in old age populations in comparison with younger age groups: a systematic review. Ageing Res Rev. 2013;12:151–156.
    1. Nimnuan C, Hotopf M, Wessely S. Medically unexplained symptoms: an epidemiological study in seven specialities. J Psychosom Res. 2001;51:361–367.
    1. Maiden NL, Hurst NP, Lochhead A, Carson AJ, Sharpe M. Medically unexplained symptoms in patients referred to a specialist rheumatology service: prevalence and associations. Rheumatology (Oxford) 2003;42:108–112.
    1. Snijders TJ, de Leeuw FE, Klumpers UM, Kappelle LJ, van Gijn J. Prevalence and predictors of unexplained neurological symptoms in an academic neurology outpatient clinic—an observational study. J Neurol. 2004;251:66–71.
    1. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry. 2004;184:470–476.
    1. Verhaak PF, Meijer SA, Visser AP, Wolters G. Persistent presentation of medically unexplained symptoms in general practice. Fam Pract. 2006;23:414–420.
    1. Rosendal M, Olde Hartman TC, Aamland A, et al. „Medically unexplained“ symptoms and symptom disorders in primary care: prognosis based recognition and classification. BMC Fam Pract. 2017;18
    1. Lieb R, Zimmermann P, Friis RH, Höfler M, Tholen S, Wittchen HU. The natural course of DSM-IV somatoform disorders and syndromes among adolescents and young adults: a prospective longitudinal community study. Eur Psychiatry. 2002;17:321–331.
    1. Jackson JL, Kroenke K. Prevalence, impact, and prognosis of multisomatoform disorder in primary care: a 5-year follow up study. Psychosom Med. 2008;70:430–434.
    1. Steinbrecher N, Hiller W. Course and prediction of somatoform disorder and medically unexplained symptoms in primary care. Gen Hosp Psychiatry. 2011;33:318–326.
    1. Olde Hartman TC, Borghuis MS, Lucassen PL, van de Laar FA, Speckens AE, van Weel C. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. J Psychosom Res. 2009;66:363–377.
    1. Budtz-Lilly A, Vestergaard M, Fink P, Carlsen AH, Rosendal M. The prognosis of bodily distress syndrome: a cohort study in primary care. Gen Hosp Psychiatry. 2015;37:560–566.
    1. Wiborg JF, Gieseler D, Fabisch AB, Voigt K, Lautenbach A, Löwe B. Suicidality in primary care patients with somatoform disorders. Psychosom Med. 2013;75:800–806.
    1. Kämpfer N, Staufenbiel S, Wegener I, et al. Suicidality in patients with somatoform disorder—the speechless expression of anger? Psychiatry Res. 2016;246:485–491.
    1. Lan CC, Tseng CH, Chen JH, et al. Increased risk of a suicide event in patients with primary fibromyalgia and in fibromyalgia patients with concomitant comorbidities: a nationwide population-based cohort study. Medicine (Baltimore) 2016;95 e5187.
    1. Calati R, Laglaoui Bakhiyi C, Artero S, Ilgen M, Courtet P. The impact of physical pain on suicidal thoughts and behaviors: meta-analyses. J Psychiatr Res. 2015;71:16–32.
    1. Spiegel B, Schoenfeld P, Naliboff B. Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:183–193.
    1. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet. 1999;354:936–939.
    1. Olde Hartman TC, Lucassen PL, van de Lisdonk EH, Bor HH, van Weel C. Chronic functional somatic symptoms: a single syndrome? Br J Gen Pract. 2004;54:922–927.
    1. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med. 2003, 65,:528–533.
    1. Fink P, Toft T, Hansen MS, Ørnbøl E, Olesen F. Symptoms and syndromes of bodily distress: an exploratory study of 978 internal medical, neurological, and primary care patients. Psychosom Med. 2007;69:30–39.
    1. Kanaan RA, Lepine JP, Wessely SC. The association or otherwise of the functional somatic syndromes. Psychosom Med. 2007;69:855–859.
    1. Riedl A, Schmidtmann M, Stengel A, et al. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res. 2008;64:573–582.
    1. Fink P, Schröder A. One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders. J Psychosom Res. 2010;68:415–426.
    1. Lieb R, Meinlschmidt G, Araya R. Epidemiology of the association between somatoform disorders and anxiety and depressive disorders: an update. Psychosom Med. 2007;69:860–863.
    1. Lowe B, Spitzer RL, Williams JB, Mussell M, Schellberg D, Kroenke K. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry. 2008;30:191–199.
    1. Hanel G, Henningsen P, Herzog W, et al. Depression, anxiety, and somatoform disorders: vague or distinct categories in primary care? Results from a large cross-sectional study. J Psychosom Res. 2009;67:189–197.
    1. Kohlmann S, Gierk B, Hilbert A, Brahler E, Lowe B. The overlap of somatic, anxious and depressive syndromes: a population-based analysis. J Psychosom Res. 2016;90:51–56.
    1. Hatcher S, Gilmore K, Pinchen K. A follow-up study of patients with medically unexplained symptoms referred to a liaison psychiatry service. Int J Psychiatry Med. 2011;41:217–227.
    1. Stone J, Carson A, Duncan R, et al. Symptoms unexplained by organic disease in 1144 new neurology out-patients: how often does the diagnosis change at follow-up? Brain. 2009;132:2878–2888.
    1. Eikelboom EM, Tak LM, Roest AM, Rosmalen JGM. A systematic review and meta-analysis of the percentage of revised diagnoses in functional somatic symptoms. J Psychosom Res. 2016;88:60–67.
    1. Konnopka A, Schaefert R, Heinrich S, et al. Economics of medically unexplained symptoms: a systematic review of the literature. Psychother Psychosom. 2012;81:265–275.
    1. Rask MT, Ørnbøl E, Rosendal M, Fink P. Long-term outcome of bodily distress syndrome in primary care: a follow-up study on health care costs, work disability, and self-rated health. Psychosom Med. 2017;79:345–357.
    1. Oxford Centre for Evidence-Based Medicine (2009) Levels of evidence. (last accessed on 10 August 2018)
    1. Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349 g5630.
    1. Beauchamp TL, Childress JF. Principles of biomedical ethics. Oxford: Oxford University Press. 2013
    1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF) AWMF-Regelwerk Leitlinien. (last accessed on 31 August 2018)
    1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), eds. Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI) - Fassung 2005/2006 + Domäne 8. (last accessed on 10 August 2018)
    1. Berens S, Hausteiner-Wiehle C, Sattel H, et al. Schweregrad-gestuftes, kooperatives und koordiniertes Versorgungsmodell für Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden. Psychologische Medizin: Österreichische Fachzeitschrift für medizinische Psychologie, Psychosomatik und Psychotherapie. 2016;4:13–22.
    1. Almquist E, Toernblom H, Simreìn M. Practical management of irritable bowel syndrome: a clinical review. Minerva gastroenterologica e dietologica. 2016;62:30–48.
    1. van der Feltz-Cornelis CM, Hoedeman R, Keuter EJ, Swinkels JA. Presentation of the multidisciplinary guideline Medically Unexplained Physical Symptoms (MUPS) and somatoform disorder in the Netherlands: disease management according to risk profiles. J Psychosom Res. 2012;72:168–169.
    1. Salmon P, Peters S, Stanley I. Patients‘ perceptions of medical explanations for somatisation disorders: qualitative analysis. BMJ. 1999;318:372–376.
    1. Arbeitskreis PISO (Hrsg.) Psychodynamisch-Interpersonelle Therapie bei somatoformen Störungen (PISO). Eine manualisierte Kurzzeitintervention. Göttingen: Hogrefe Verlag. 2012;47
    1. Schaefert R, Bölter R, Faber R, Claudia Kaufmann C. Tangential, nicht frontal. Annäherung an eine schwierige Patientengruppe. Psychotherapie im Dialog. 2008;9:252–259.
    1. Rask MT, Carlsen AH, Budtz-Lilly A, Rosendal M. Multiple somatic symptoms in primary care patients: a cross-sectional study of consultation content, clinical management strategy and burden of encounter. BMC Fam Pract. 2016;17
    1. Olde Hartman TC, Woutersen-Koch H, van der Horst HE. Medically unexplained symptoms: evidence, guidelines, and beyond. Br J Gen Pract. 2013;63:625–626.
    1. Brownell AK, Atkins C, Whiteley A, Woollard RF, Kornelsen J. Clinical practitioners‘ views on the management of patients with Medically Unexplained Physical Symptoms (MUPS): a qualitative study. BMJ Open. 2016;6 e012379.
    1. Murray AM, Toussaint A, Althaus A, Lowe B. The challenge of diagnosing non-specific, functional, and somatoform disorders: a systematic review of barriers to diagnosis in primary care. J Psychosom Res. 2016;80:1–10.
    1. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268:760–765.
    1. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 1993;118:81–90.
    1. Kroenke K. A practical and evidence-based approach to common symptoms: a narrative review. Ann Intern Med. 2014;161:579–586.
    1. Evens A, Vendetta L, Krebs K, Herath P. Medically unexplained neurologic symptoms: a primer for physicians who make the initial encounter. Am J Med. 2015;128:1059–1064.
    1. Kelly M, Tink W, Nixon L, Dornan T. Losing touch? Refining the role of physical examination in family medicine. Can Fam Physician. 2015;61:1041–1043.
    1. Pincus T, Holt N, Vogel S, et al. Cognitive and affective reassurance and patient outcomes in primary care: a systematic review. Pain. 2013;154:2407–2416.
    1. Mann B, Wilson H. Diagnosing somatisation in adults in the first consultation: moving beyond diagnosis by exclusion. Br J Gen Pract. 2013;63:607–608.
    1. Lorenzer A. Interaktion, Sprache und szenisches Verstehen. Psyche. 1983;37:97–115.
    1. Riess H, Kraft-Todd G. EM.P.A.T.H.Y.: a tool to enhance nonverbal communication between clinicians and their patients. Acad Med. 2014;89:1108–1112.
    1. Axt-Adam P, van der Wouden JC, van der Does E. Influencing behavior of physicians ordering laboratory tests: a literature study. Med Care. 1993;31:784–794.
    1. van Wijk MA, van der Lei J, Mosseveld M, Bohnen AM, van Bemmel JH. Assessment of decision support for blood test ordering in primary care. a randomized trial. Ann Intern Med. 2001;134:274–281.
    1. Koch H, van Bokhoven MA, ter Riet G, et al. Ordering blood tests for patients with unexplained fatigue in general practice: what does it yield? Results of the VAMPIRE trial. Br J Gen Pract. 2009;59:e93–e100.
    1. Epstein RM, Hadee T, Carroll J, Meldrum SC, Lardner J, Shields CG. “Could this be something serious?” Reassurance, uncertainty, and empathy in response to patients’ expressions of worry. J Gen Intern Med. 2007;22:1731–1739.
    1. Anderson M, Hartz A, Nordin T, et al. Community physicians’ strategies for patients with medically unexplained symptoms. Fam Med. 2008;40:111–118.
    1. Giroldi E, Veldhuijzen W, Leijten C, et al. ‚No need to worry‘: an exploration of general practitioners‘ reassuring strategies. BMC Fam Pract. 2014;15:133.
    1. Hasenbring MI, Pincus T. Effective reassurance in primary care of low back pain: what messages from clinicians are most beneficial at early stages? Clin J Pain. 2015;31:133–136.
    1. Musekamp G, Gerlich C, Ehlebracht-König I, Faller H, Reusch A. Evaluation of a self-management patient education program for patients with fibromyalgia syndrome: study protocol of a cluster randomized controlled trial. BMC Musculoskelet Disord. 2016;17
    1. Smith RC, Lyles JS, Gardiner JC, et al. Primary care clinicians treat patients with medically unexplained symptoms: a randomized controlled trial. J Gen Intern Med. 2006;21:671–677.
    1. Smith RC, Gardiner JC, Luo Z, Schooley S, Lamerato L, Rost K. Primary care physicians treat somatization. J Gen Intern Med. 2009;24:829–832.
    1. Aiarzaguena JM, Grandes G, Gaminde I, Salazar A, Sanchez A, Arino J. A randomized controlled clinical trial of a psychosocial and communication intervention carried out by GPs for patients with medically unexplained symptoms. Psychol Med. 2007;37:283–294.
    1. Pols RG, Battersby MW. Coordinated care in the management of patients with unexplained physical symptoms: depression is a key issue. Med J Aust. 2008;188(12 Suppl):133–137.
    1. van der Weijden T, van Velsen M, Dinant GJ, van Hasselt CM, Grol R. Unexplained complaints in general practice: prevalence, patients’ expectations, and professionals‘ test-ordering behavior. Med Decis Making. 2003;23:226–231.
    1. Heijmans M, Olde Hartman TC, van Weel-Baumgarten E, Dowrick C, Lucassen PL, van Weel C. Experts‘ opinions on the management of medically unexplained symptoms in primary care. A qualitative analysis of narrative reviews and scientific editorials. Fam Pract. 2011;28:444–455.
    1. Fink P, Rosendal M, Toft T. Assessment and treatment of functional disorders in general practice: the extended reattribution and management model—an advanced educational program for nonpsychiatric doctors. Psychosomatics. 2002;43:93–131.
    1. Larisch A, Schweickhardt A, Wirsching M, Fritzsche K. Psychosocial interventions for somatizing patients by the general practitioner: a randomized controlled trial. J Psychosom Res. 2004;57:507–514.
    1. Rief W, Martin A, Rauh E, Zech T, Bender A. Evaluation of general practitioners‘ training: how to manage patients with unexplained physical symptoms. Psychosomatics. 2006;47:304–311.
    1. Rosendal M, Olesen F, Fink P, Toft T, Sokolowski I, Bro F. A randomized controlled trial of brief training in the assessment and treatment of somatization in primary care: effects on patient outcome. Gen Hosp Psychiatry. 2007;29:364–373.
    1. Smith RC, Gardiner JC, Luo Z, Schooley S, Lamerato L, Rost K. Primary care physicians treat somatization. J Gen Intern Med. 2009;24:829–832.
    1. Weiland A, Blankenstein AH, van Saase JL, et al. Training medical specialists to communicate better with patients with Medically Unexplained Physical Symptoms (MUPS). A randomized, controlled trial. PLoS One. 2015;10 e0138342.
    1. Warner A, Walters K, Lamahewa K, Buszewicz M. How do hospital doctors manage patients with medically unexplained symptoms: a qualitative study of physicians. J R Soc Med. 2017;110:65–72.
    1. Yon K, Habermann S, Rosenthal J, et al. Improving teaching about medically unexplained symptoms for newly qualified doctors in the UK: findings from a questionnaire survey and expert workshop. BMJ Open. 2017;7 e014720.
    1. Schaefert R, Benedikt G, Sauer N, et al. Früherkennung und Behandlung funktioneller/somatoformer Beschwerden in der Allgemeinarztpraxis - das FUNKTIONAL-Forschungsprojekt. Notfall & Hausarztmedizin. 2005;31:527–536.
    1. Rudolf G, Henningsen P. Die psychotherapeutische Behandlung somatoformer Störungen. Z Psychsom Med Psychother. 2003;49:3–19.
    1. Langewitz W. Patientenzentrierte Kommunikation Psychosomatische Medizin. Theoretische Modelle und klinische Praxis. In: Adler RH, Herzog W, Joraschky P, et al., editors. Elsevier, Urban & Fischer. München: 2011. pp. 338–347.
    1. Rolfe A, Burton C. Reassurance after diagnostic testing with a low pretest probability of serious disease: systematic review and meta-analysis. JAMA Intern Med. 2013;173:407–416.
    1. Kroenke K. Diagnostic testing and the illusory reassurance of normal results: comment on „Reassurance after diagnostic testing with a low pretest probability of serious disease“. JAMA Intern Med. 2013;173:416–417.
    1. Petrie KJ, Sherriff R. Normal diagnostic test results do not reassure patients. Evid Based Med. 2014;19
    1. Widder B, Dertwinkel R, Egle UT, Foerster K, Schiltenwolf M. Leitlinie für die Begutachtung von Schmerzen. Psychotherapeut. 2007;52:334–346.
    1. Burton C, Lucassen P, Aamland A, Olde Hartman T. Explaining symptoms after negative tests: towards a rational explanation. J R Soc Med. 2015;108:84–88.
    1. Vedsted P, Christensen MB, Sørensen HT, Fink P, Olesen F. Special status consultation for frequent attenders Who are the candidates? J Public Health Med. 2002;24:53–57.
    1. Fink P, Rosendal M, Toft T. Assessment and treatment of functional disorders in general practice: the extended reattribution and management model—an advanced educational program for nonpsychiatric doctors. Psychosomatics. 2002;43:93–131.
    1. Bahrs O. Der Bilanzierungsdialog. Der Mensch. 2007;38:29–32.
    1. Stephens G, Derry S, Moore RA. Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2016;6 CD011889.
    1. Derry S, Wiffen PJ, Häuser W, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017;3 CD012332.
    1. Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2014;7 CD007533.
    1. Kleinstäuber M, Witthöft M, Steffanowski A, van Marwijk H, Hiller W, Lambert MJ. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev. 2014;11 CD010628.
    1. Walitt B, Klose P, Üçeyler N, Phillips T, Häuser W. Antipsychotics for fibromyalgia in adults. Cochrane Database Syst Rev. 2016;6 CD011804.
    1. Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66:411–420.
    1. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109
    1. Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015;54:243–249.
    1. Furlan AD, Giraldo M, Baskwill A, Irvin E, Imamura M. Massage for low-back pain. Cochrane Database Syst Rev. 2015;9 CD001929.
    1. Naumann J, Sadaghiani C. Therapeutic benefit of balneotherapy and hydrotherapy in the management of fibromyalgia syndrome: a qualitative systematic review and meta-analysis of randomized controlled trials. Arthritis Res Ther. 2014;16 R141.
    1. Salazar AP, Stein C, Marchese RR, Plentz RD, Pagnussat AS. Electric stimulation for pain relief in patients with fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:15–25.
    1. Müller A, Franke H, Resch KL, Fryer G. Effectiveness of osteopathic manipulative therapy for managing symptoms of irritable bowel syndrome: a systematic review. J Am Osteopath Assoc. 2014;114:470–479.
    1. Martins WR, Blasczyk JC, Aparecida Furlan de Oliveira M, Lagoa Goncalves KF, Bonini-Rocha AC, Dugailly PM. Efficacy of musculoskeletal manual approach in the treatment of temporomandibular joint disorder: a systematic review with meta-analysis. Man Ther. 2016;21:10–17.
    1. Mesa-Jiménez JA, Lozano-López C, Angulo-Díaz-Parreño S, Rodríguez-Fernández ÁL, De-la-Hoz-Aizpurua JL, Fernández-de-Las-Peñas C. Multimodal manual therapy vs pharmacological care for management of tension type headache: a meta-analysis of randomized trials. Cephalalgia. 2015;35:1323–1332.
    1. Lam M, Galvin R, Curry P. Effectiveness of acupuncture for nonspecificchronic low back pain: a systematic review and meta-analysis. Spine (Phila Pa1976) 2013;38:2124–2138.
    1. Ainpradub K, Sitthipornvorakul E, Janwantanakul P, van der Beek AJ. Effect of education on non-specific neck and low back pain: a meta-analysis of randomized controlled trials. Man Ther. 2016;22:31–41.
    1. Anheyer D, Haller H, Barth J, Lauche R, Dobos G, Cramer H. Mindfulness-based stress reduction for treating low back pain: a systematic review and meta-analysis. Ann Intern Med. 2017;166:799–807.
    1. Searle A, Spink M, Ho A, Chuter V. Exercise interventions for the treatment of chronic low back pain: a systematic review and meta-analysis of randomised controlled trials. Clin Rehabil. 2015;29:1155–1167.
    1. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. Cochrane Database Syst Rev. 2014;9 CD000963.
    1. Waterschoot FP, Dijkstra PU, Hollak N, de Vries HJ, Geertzen JH, Reneman MF. Dose or content? Effectiveness of pain rehabilitation programs for patients with chronic low back pain: a systematic review. Pain. 2014;155:179–189.
    1. van der Feltz-Cornelis CM, van Os TW, van Marwijk HW, Leentjens AF. Effect of psychiatric consultation models in primary care. A systematic review and meta-analysis of randomized clinical trials. J Psychosom Res. 2010;68:521–533.
    1. Hoedeman R, Blankenstein AH, van der Feltz-Cornelis CM, Krol B, Stewart R, Groothoff JW. Consultation letters for medically unexplained physical symptoms in primary care. Cochrane Database Syst Rev. 2010;12 CD006524.
    1. Koelen JA, Houtveen JH, Abbass A, et al. Effectiveness of psychotherapy for severe somatoform disorder: meta-analysis. Br J Psychiatry. 2014;204:12–19.
    1. Zech N, Hansen E, Bernardy K, Häuser W. Efficacy, acceptability and safety of guided imagery/hypnosis in fibromyalgia—a systematic review and meta-analysis of randomized controlled trials. Eur J Pain. 2017;21:217–227.
    1. van den Bergh O, Witthöft M, Petersen S, Brown RJ. Symptoms and the body: taking the inferential leap. Neurosci Biobehav Rev. 2017;74(Pt A):185–203.
    1. Varinen A, Kosunen E, Mattila K, Koskela T, Sumanen M. The relationship between childhood adversities and fibromyalgia in the general population. J Psychosom Res. 2017;99:137–142.
    1. Guthrie E. Adaptation of the psychodynamic-interpersonal model to work with medically unexplained symptoms Psychodynamic interpersonal therapy: a conversational model. In: Barkham M, Guthrie E, Hardy GE, Margison F, editors. Sage. London: 2017.
    1. Probst T, von Heymann F, Zaudig M, et al. Effektivität stationärer psychosomatischer Krankenhausbehandlung - Ergebnisse einer multizentrischen Katamnesestudie. Z Psychosom Med Psychother. 2009;55:409–420.
    1. Beutel ME, von Heymann F, Bleichner F, Tritt K, Hardt J. Wie wirksam ist psychosomatische Therapie bei somatoformen Störungen? Ergebnisse einer Multicenterstudie. Z Psychosom Med Psychother. 2014;60:17–24.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever